BWA
NPCE icon

Basecamp Wealth Advisors’s Neuropace NPCE Stock Holding History

Basecamp Wealth Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350 Sell
22
-7
-24% -$113 ﹤0.01% 1677
2026
Q1 		$381 Buy
+29
New +$435 ﹤0.01% 1782

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Basecamp Wealth Advisors's NPCE Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Neuropace (NPCE) stake by 24% in Q2 2026, selling an estimated $113 and leaving 22 shares worth $350. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

Basecamp Wealth Advisors first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $381 in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Basecamp Wealth Advisors held 22 shares of Neuropace worth $350 as of Q2 2026.
  • Basecamp Wealth Advisors sold 7 Neuropace shares in Q2 2026, an estimated $113.
  • Neuropace made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1677 holding.
  • Basecamp Wealth Advisors first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Neuropace position peaked at $381 in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.